Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
ICU MEDICAL Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are an ICU Medical investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
On April 22, 2025, Bloomberg reported that the Federal Drug Administration (“FDA”) had issued a Warning Letter to ICU Medical “regarding unapproved changes to its infusion pumps.” The Warning Letter, dated April 4, 2025, which was based on an FDA inspection from July 23 through August 9, 2024, states that the Company “made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices,” and that the Company “failed to submit a premarket notification submission to [the] FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices. . . .” The Warning Letter further states that the pumps are “adulterated . . . because [the Company] does not . . . have an approved application for premarket approval (PMA) in effect.”
Following this news, the price of ICU Medical stock declined by as much as $10.72 per share, or by approximately 8%, during intraday trading. On April 22, 2025, ICU shares closed at $130.68 per share, a decline of $6.04 per share, or over 4%, from the closing price the prior day.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
View the original release on www.newmediawire.com
COMTEX_465078646/2549/2025-04-30T13:05:03